Source：
2021-04-15 17:26
Shijiazhuang Yiling Pharmaceutical, which produces Lianhua Qingwen, a commonly available over-the-counter medicine in China, has seen its sales skyrocket after the traditional Chinese medicine proved effective in the treatment of symptoms related to COVID-19.
The company s revenue grew 50 percent year-on-year in 2020 on the back of surging Lianhua Qingwen sales. Net profit hit 1.22 billion yuan ($184.3 million) last year, up some 101 percent year-on-year, the company said.
TCM has been recognized by many countries worldwide as effective in alleviating some symptoms related to the novel coronavirus, but faces challenges in being exported to markets outside China, according to the company.